Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Positron Emission Tomography Radiopharmaceuticals for Sex Steroid Hormone Receptor Imaging

Author(s): Y. Kiyono, T. Mori and H. Okazawa

Volume 19, Issue 20, 2012

Page: [3266 - 3270] Pages: 5

DOI: 10.2174/092986712801215919

Price: $65

Abstract

Understanding the expression of tumor specific receptors is important not only for tumor diagnosis but also for planning the strategy for patient treatment. Tumor receptor has been one of the most critical targets for treatment in cancer such as breast, prostate and thyroid cancers. Positron emission tomography (PET) is a part of molecular imaging techniques based on detecting the radiopharmaceuticals that can capture functional or phenotypic changes associated with pathology. The advantages of detecting tumor specific receptors by PET are its non-invasiveness, providing comprehensive information about receptor expression, avoiding the sampling errors, selecting strategy for the treatment of patients and monitoring tumor response to therapy. Hormonal therapy plays a major role in cancer treatment. Therefore, we review the PET radiopharmaceuticals for sex steroid hormone receptor imaging in this article.

Keywords: Positron emisson tomography, estrogen receptor, androgen receptor, progesterone receptor, radiopharmaceuticals, tumor specific receptors, tumor diagnosis, cancer, breast, pathology


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy